AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|
29.8 C
New York
Friday, September 4, 2026

Tag: patients

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company’s common stock to institutional or accredited investors.

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.

Exactech Reaches Consensual Agreement with Unsecured Creditors Committee, Completes Court Filing of Amended Plan

Plan Confirmation and Sale Approval Court Date Expected in Early September GAINESVILLE, Fla., July 24, 2025 /PRNewswire/ -- Exactech, a global medical technology leader, has filed...

Dr. Joel Berley Launches 2026 Scholarship to Empower Aspiring Medical Leaders Nationwide

PLANTATION, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Dr. Joel Berley, a nationally respected oral surgeon and founder of Plantation Oral Surgery, is pleased to announce the official launch of the 2026 application cycle for the Dr. Joel Berley Scholarship for Future Doctors. This prestigious academic grant reflects Dr. Berley’s enduring mission to identify and uplift undergraduate students who are poised to become catalysts for progress in medicine.

Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit

MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)
MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Omniscient and The Jacobs Institute, Inc. Announce Strategic Partnership to Pioneer Clinical Connectomics

Omniscient and The Jacobs Institute launch Connectomics Innovation Program to advance stroke recovery and neurologic care with AI-enabled software.

Minnesota Medical Technologies Announces FDA 510(k) Clearance for its Fecal Incontinence Device

STEWARTVILLE, Minn., July 24, 2025 /PRNewswire/ -- Minnesota Medical Technologies, today announced that it received FDA 510(k) clearance for its fecal incontinence device ("StaySure(™)"). ...

Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...

HealthSure 3X Launches Virtual In-Home Medical Services with Improved Access to Quality Care

NEWARK, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- HealthSure 3X, an online health solutions company headquartered in New Jersey, has introduced a fully integrated platform where patients can avail themselves of licensed healthcare professionals at home using virtual in-home medical care. This method caters to growing needs for accessible and flexible healthcare while upholding professional standards and patient safety.

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation...

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients